RCMI Coordinating Center (RCMI CC) Header Logo

Cimona V. Hinton

TitleDr.
Faculty RankProfessor
InstitutionClark Atlanta University
DepartmentCenter for Cancer Research and Therapeutic Development
Address223 James P. Brawley Dr. SW
RCST, Room 4017B
Center for Cancer Research and Therapeutic Development
Atlanta GA 30312
Phone4048808134
Fax4048808065
vCardDownload vCard

    Collapse Affiliation 

    Collapse Overview 
    Collapse overview
    Our laboratory focuses on mechanisms responsible for cancer cell metastasis at both the cellular and molecular levels. In this regard, we currently study the involvement of chemokine pathways that induce motility of cancer cells. The primary objective is to study how the CXCR4/CXCL12 signaling axis may aid in the migration and invasion of foreign tissues under cancerous condition. This system is studied in prostate and breast cancer cells.

    The following are some of the specific projects in our laboratory:
    · The role of tumor suppressors in CXCR4-mediated metastasis.
    · The role of cannabinoinds in anti-tumorigenesis and anti-cancinogenesis
    Proinflammatory macrophages in prostate cancer initiation and tumor progresion


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bai L, Li X, Yang Y, Zhao R, White EZ, Danaher A, Bowen NJ, Hinton CV, Cook N, Li D, Wu AY, Qui M, Du Y, Fu H, Kucuk O, Wu D. Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models. Transl Oncol. 2023 Aug; 34:101707. PMID: 37271121.
      Citations:    
    2. Campbell T, Hawsawi O, Henderson V, Dike P, Hwang BJ, Liadi Y, White EZ, Zou J, Wang G, Zhang Q, Bowen N, Scott D, Hinton CV, Odero-Marah V. Novel roles for HMGA2 isoforms in regulating oxidative stress and sensitizing to RSL3-Induced ferroptosis in prostate cancer cells. Heliyon. 2023 Apr; 9(4):e14810. PMID: 37113783.
      Citations:    
    3. Pennant NM, Hinton CV. The evolution of cannabinoid receptors in cancer. WIREs Mech Dis. 2023 Jul-Aug; 15(4):e1602. PMID: 36750231.
      Citations: 5     Fields:    Translation:HumansAnimals
    4. Tchounwou PB, Malouhi M, Ofili EO, Fern?ndez-Repollet E, Sarpong DF, Yanagihara R, Aguilera RJ, Ay?n C, Chen X, Dasmahapatra A, Gao S, Hinton CV, Holt R, Kolesnichenko V, Powell MD, Merchant F, Redda KK, Roche-Lima A, Shikuma CM, Stevens JJ, Torres JA, Trotter RT, Wachira J, Wang P, Wells KJ, White J, Wu Y. Research Infrastructure Core Facilities at Research Centers in Minority Institutions: Part I-Research Resources Management, Operation, and Best Practices. Int J Environ Res Public Health. 2022 12 17; 19(24). PMID: 36554864.
      Citations: 1     Fields:    Translation:Humans
    5. Henry Akintobi T, Sheikhattari P, Shaffer E, Evans CL, Braun KL, Sy AU, Mancera B, Campa A, Miller ST, Sarpong D, Holliday R, Jimenez-Chavez J, Khan S, Hinton C, Sellars-Bates K, Ajewole V, Teufel-Shone NI, McMullin J, Suther S, Kimbro KS, Taylor L, Velez Vega CM, Williams C, Perry G, Zuchner S, Marzan Rodriguez M, Tchounwou PB. Community Engagement Practices at Research Centers in U.S. Minority Institutions: Priority Populations and Innovative Approaches to Advancing Health Disparities Research. Int J Environ Res Public Health. 2021 06 21; 18(12). PMID: 34205781.
      Citations: 6     Fields:    Translation:Humans
    6. White EZ, Pennant NM, Carter JR, Hawsawi O, Odero-Marah V, Hinton CV. Serum deprivation initiates adaptation and survival to oxidative stress in prostate cancer cells. Sci Rep. 2020 07 27; 10(1):12505. PMID: 32719369.
      Citations: 20     Fields:    Translation:HumansCells
    7. Dougan J, Hawsawi O, Burton LJ, Edwards G, Jones K, Zou J, Nagappan P, Wang G, Zhang Q, Danaher A, Bowen N, Hinton C, Odero-Marah VA. Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer. Int J Mol Sci. 2019 Jun 21; 20(12). PMID: 31234468.
      Citations: 15     Fields:    Translation:HumansCells
    8. Scarlett KA, White EZ, Coke CJ, Carter JR, Bryant LK, Hinton CV. Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Ga13/RhoA-mediated Migration. Mol Cancer Res. 2018 04; 16(4):728-739. PMID: 29330286.
      Citations: 26     Fields:    Translation:HumansCells
    9. Coke CJ, Scarlett KA, Chetram MA, Jones KJ, Sandifer BJ, Davis AS, Marcus AI, Hinton CV. Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. J Biol Chem. 2016 May 06; 291(19):9991-10005. PMID: 26841863.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    10. Smith B, Randle D, Mezencev R, Thomas L, Hinton C, Odero-Marah V. Camalexin-induced apoptosis in prostate cancer cells involves alterations of expression and activity of lysosomal protease cathepsin D. Molecules. 2014 Apr 02; 19(4):3988-4005. PMID: 24699144.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    11. Chang MA, Morgado M, Warren CR, Hinton CV, Farach-Carson MC, Delk NA. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines. Prostate. 2014 Feb; 74(2):149-63. PMID: 24122957.
      Citations: 16     Fields:    Translation:HumansCells
    12. Jones KJ, Chetram MA, Bethea DA, Bryant LK, Odero-Marah V, Hinton CV. Cysteine (C)-X-C Receptor 4 Regulates NADPH Oxidase-2 During Oxidative Stress in Prostate Cancer Cells. Cancer Microenviron. 2013 Sep 28. PMID: 24078461.
      Citations:    
    13. Chetram MA, Hinton CV. ROS-mediated regulation of CXCR4 in cancer. Front Biol (Beijing). 2013 Jun 01; 8(3). PMID: 24223583.
      Citations:    
    14. Don-Salu-Hewage AS, Chan SY, McAndrews KM, Chetram MA, Dawson MR, Bethea DA, Hinton CV. Cysteine (C)-x-C receptor 4 undergoes transportin 1-dependent nuclear localization and remains functional at the nucleus of metastatic prostate cancer cells. PLoS One. 2013; 8(2):e57194. PMID: 23468933.
      Citations: 34     Fields:    Translation:HumansCells
    15. Chetram MA, Bethea DA, Odero-Marah VA, Don-Salu-Hewage AS, Jones KJ, Hinton CV. ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem. 2013 Apr; 376(1-2):63-71. PMID: 23315288.
      Citations: 32     Fields:    Translation:HumansCells
    16. Smith BA, Neal CL, Chetram M, Vo B, Mezencev R, Hinton C, Odero-Marah VA. The phytoalexin camalexin mediates cytotoxicity towards aggressive prostate cancer cells via reactive oxygen species. J Nat Med. 2013 Jul; 67(3):607-18. PMID: 23179315.
      Citations: 8     Fields:    Translation:HumansCells
    17. Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 2012 Aug; 32(4):190-5. PMID: 22737980.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    18. Chetram MA, Don-Salu-Hewage AS, Hinton CV. ROS enhances CXCR4-mediated functions through inactivation of PTEN in prostate cancer cells. Biochem Biophys Res Commun. 2011 Jul 01; 410(2):195-200. PMID: 21627959.
      Citations: 26     Fields:    Translation:HumansCells
    19. Chetram MA, Odero-Marah V, Hinton CV. Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells. Mol Cancer Res. 2011 Jan; 9(1):90-102. PMID: 21076047.
      Citations: 30     Fields:    Translation:HumansCells
    20. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2010 Feb; 27(2):97-105. PMID: 18814042.
      Citations: 62     Fields:    Translation:HumansCells
    21. Hinton CV, Avraham S, Avraham HK. Contributions of integrin-linked kinase to breast cancer metastasis and tumourigenesis. J Cell Mol Med. 2008 Sep-Oct; 12(5A):1517-26. PMID: 18363848.
      Citations: 7     Fields:    Translation:HumansAnimals
    22. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007 Jun; 4(6):e186. PMID: 17550303.
      Citations: 128     Fields:    Translation:HumansAnimalsCells
    23. Hinton CV, Fitzgerald LD, Thompson ME. Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1. Exp Cell Res. 2007 May 15; 313(9):1735-44. PMID: 17428466.
      Citations: 16     Fields:    Translation:HumansCells
    Hinton's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (131)
    Explore
    _
    Co-Authors (24)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support